The main prognostic factors and why minimal residual disease is becoming crucial in multiple myeloma
Myeloma 2016: Panel discussion on the new treatment paradigm
Gareth Morgan et al.
The aims of the Genomics England CLL pilot
Is FISH becoming obsolete in multiple myeloma?
The multi-cohort SCHOLAR-1 study of refractory aggressive DLBCL